Neumonía eosinofílica crónica secuandaria a levetiracetam

  1. Pazos-Area, Luis Alberto 1
  2. Ramos-Hernández, Cristina 1
  3. Núñez-Fernández, Marta 1
  4. González-Montaos, Almudena 1
  5. Fernández-Villar, José Alberto 1
  1. 1 Departamento de Neumología, Hospital Álvaro Cunqueiro. Neumo Vigo I+i. Instituto de Investigación Sanitaria Galicia Sur (IISGS). Vigo, España
Journal:
Revista Española de Casos Clínicos en Medicina Interna (RECCMI)

ISSN: 2530-0792

Year of publication: 2022

Volume: 7

Issue: 1

Pages: 16-18

Type: Article

DOI: 10.32818/RECCMI.A7N1A6 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Revista Española de Casos Clínicos en Medicina Interna (RECCMI)

Sustainable development goals

Abstract

Eosinophilic pulmonary diseases constitute a very heterogeneous group of diseases that share clinical manifestations, radiological and/or laboratory findings. Therefore, it is necessary to know the diagnostic criteria for each disease. Chronic idiopathic eosinophilic pneumonia is the most common eosinophilic pneumonia in non-tropical areas where parasitic infections is low. If a clear cause is identified, the most frequent is secondary to drugs and/or toxins. We present the case of a 21-year-old man diagnosed with chronic eosinophilic pneumonia secondary to treatment with levetiracetam, a generally safe and widely accepted drug in routine clinical practice. A search for the etiology of eosinophilic pulmonary diseases is essential, because identifying a possible cause would allow the withdrawal of the causative agent and to start corticosteroid therapy, so we could prevent the associated morbidity and mortality.

Bibliographic References

  • Arnedillo Muñoz A, Hidalgo Molina A. Enfermedades pulmonares eosinofílicas. 2018. Manual Separ Neumología y Cirugía Torácica. Ec-Europe. ISBN 978-84-09-01621-1.
  • Newsome SD, Xue LY, Jennings T, Castaneda GY. Levetiracetam-Induced Diffuse Interstitial Lung Disease. J Child Neurol. 2007; 22(5): 628-30. https://doi.org/10.1177/0883073807302602.
  • Cottin V. Eosinophilic Lung Diseases. Clin Chest Med. 2016; 37(3): 535-56. https://doi.org/10.1016/j.ccm.2016.04.015.
  • Crowe M, Robinson D, Sagar M, Chen L, Ghamande S. Chronic eosinophilic pneumonia: clinical perspectives. Ther Clin Risk Manag. 2019; 15: 397-403. https://doi.org/10.2147/TCRM.S157882.
  • Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, Weller PF, Hellmann A, Metzgeroth G, Leiferman KM, Arock M, Butterfield JH, Sperr WR, Sotlar K, Vandenberghe P, Haferlach T, Simon HU, Reiter A, Gleich GJ.Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012; 130(3): 607-612.e9. https://doi.org/10.1016/j.jaci.2012.02.019.
  • Fagan A, Fuld J, Soon E.Levetiracetam-induced eosinophilic pneumonia. BMJ Case Rep. 2017; 2017: bcr2016219121. doi: https://doi.org/10.1136/bcr-2016-219121.
  • Taweesedt PT, Nordstrom CW, Stoeckel J, Dumic I.Pulmonary Manifestations of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Systematic Review.Biomed Res Int. 2019; 2019: 7863815. doi: https://doi.org/10.1155/2019/7863815.
  • Dar WR, Sofi N, Latief M, Dar IA, Kasana BA. Levetiracetam induced drug reaction with eosinophilia and systemic symptom syndrome. Indian J Dermatol. 2016; 61(2): 235. doi: https://doi.org/10.4103/0019-5154.177777.
Data source: Dialnet